Teva Pharmaceuticals Breaks Ground and Commences Construction of New Facility
Teva joins the city of Overland Park
Watch a video recap of the groundbreaking event.
Overland Park, KS (July 10, 2012) – Yesterday marked the official start of construction for Teva’s new facility in Overland Park, Kansas. Teva leadership, politicians and other instrumental parties attended this exciting event.
This new office building is scheduled to be completed in Q3 of 2013 and will offer workspace for approximately 350 employees. Upon completion, this site will contain a five story Class A 150,000 square foot office building with expansion capability to build an additional 100,000 square foot building.
“We look forward to completing the development of this world class office facility for Teva Pharmaceuticals on one of the most unique and highly visible sites in all of Johnson County,” said Kenneth G. Block, President of Block Development Company.
This new building will be located at 11100 Nall Avenue, in Overland Park, Kansas. The 18-acre site was formerly owned by Sprint and sold to Block Development Company. The site was broken into three parcels, two of which Teva will occupy.
“This is an exciting development for Teva’s U.S. Brand Pharmaceuticals group and we are looking forward to establishing a presence in the Overland Park community,” said Larry Downey, EVP for Teva U.S. Brand Pharmaceuticals.
“The addition of Teva Pharmaceuticals to Overland Park is a wonderful asset for this nationally recognized community,” said Mayor Carl Gerlach. “A successful community is truly a reflection of its people and businesses. I know with Teva’s proven success and leadership, Overland Park will benefit in so many ways.”
Teva looks forward to the new opportunities that this site will offer and is honored to be so graciously welcomed into the city of Overland Park.
Denise Bradley, Teva Pharmaceuticals
Teva North America is a subsidiary of Teva Pharmaceuticals Ltd. In North America, Teva has locations in 13 states, District of Columbia, Canada and Puerto Rico and more than 9,000 employees. In fact, one in every seven prescriptions dispensed in the U.S. is a Teva product.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), headquartered in Israel, is a leading global pharmaceutical company, committed to providing consumers with access to high-quality healthcare by developing, producing and marketing affordable generic, innovative and specialty products, as well as active pharmaceutical ingredients.
The Company is the largest maker of generic pharmaceutical products, has a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. The branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics.